Assertio Holdings, Inc. (ASRT)

Assertio Holdings, Inc. stock has trended up in the past six months. A 1-for-15 reverse stock split became effective on December 26, 2025, to maintain its Nasdaq listing. On March 16, 2026, Assertio reported its fourth quarter and full year 2025 financial results, showing lower revenue and a wider net loss, but provided 2026 net product sales guidance, beating EPS expectations but missing revenue expectations for Q4 2025. Assertio agreed to be acquired by Garda Therapeutics for $18 per share, leading to a downgrade to "Hold" by Maxim analysts. Cosette Pharmaceuticals acquired SYMPAZAN and additional products from Assertio. The company's stock price increased in the past month and six months.

Explicit information regarding the demand seasonality for Assertio Holdings, Inc.'s products and services is not available in the provided search results. The company's focus on products for chronic conditions, oncology, and pain management suggests that demand might be relatively stable rather than highly seasonal, as these conditions generally require ongoing treatment. The company's strategy to manage distribution transitions for products like Rolvedon to ensure uninterrupted patient supply also implies a consistent demand pattern.

Assertio Holdings, Inc. is a pharmaceutical company focused on bringing differentiated products to patients, operating in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. The company's portfolio addresses therapeutic areas such as neurology, oncology, hospital, and pain and inflammation. Major products include INDOCIN, SYMPAZAN, CAMBIA, SPRIX, ROLVEDON, Otrexup and ZIPSOR.

Assertio Holdings, Inc. provides pharmaceutical products to patients in the United States. Its principal executive offices are located in Lake Forest, Illinois, and its operations and sales are primarily focused within the U.S. pharmaceutical and medicinal manufacturing landscape.

Information specifically detailing "brand reputation" events for Assertio Holdings, Inc. in the past year is not explicitly available in the provided search results. The company's past performance has been described as highly volatile and inconsistent, marked by acquisition-driven revenue spikes followed by declines and significant losses, which could negatively impact its reputation among investors. Assertio has struggled with profitability over the last five years and experienced severe shareholder dilution, which are factors that can affect a company's standing. Analyst downgrades reflect a cautious view from the financial community. Assertio's focus on expanding Rolvedon and Sympazan as core growth assets could contribute positively to its reputation in the healthcare space.

Assertio Holdings, Inc. has a mix of institutional and individual owners. Major institutional owners include Nantahala Capital Management, LLC, Vanguard Group Inc., and Renaissance Technologies Llc. Major individual insider owners include Gavin Molinelli, Biovail Laboratories Inc., and Kevin C. Tang.